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Abstract
The present study attempts to investigate a potential underlying mechanism that
contributes to cognitive impairments associated with chemotherapy treatment. In
addition, it looks to investigate the potential preventative treatment using an
antidepressant agent (Fluoxetine) to reduce the effects observed by chemotherapy
treatment. One proposed explanation for Chemo Brain is a reduction in the proliferation
of new brain cells. This study was designed to investigate this mechanism and was
conducted in a series of two experiments. In experiment 1, 37 C57BL/6J male mice were
administered saline or one of two chemotherapy agents; Cyclophosphamide or
Doxorubicin over the course of eight days. Neural tissue was examined at 56 days and 6
months post chemotherapy administration to evaluate the effects of chemotherapy on
cellular proliferation. A two-way ANOVA was performed on the 56 day and 6 month
data. Analysis revealed no significant effect of treatment at either time point. A
significant effect of day was observed.
In experiment two, 41 C57BL/6J male mice underwent treatment of saline, the
chemotherapy agent 5-FU and saline, or an administration of Fluoxetine followed by an
administration of 5-FU. Similarly, cellular proliferation in the neural tissue was measured
at 56 days and 6 months post chemotherapy administration. A two-way ANOVA
revealed no significant effect of treatment at either time point but a significant effect of
time was observed. Overall, our results indicate that further research is needed to fully
understand the long-term impacts of chemotherapy on neurogenesis and the potential use
of neuroprotectant Fluoxetine as a preventative treatment.	
  While the results of this study
do not directly support the hypothesis that chemotherapy agents are capable of altering
neurogenesis, more work will be required to identify the conditions under which such
effects do or do not occur.
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INTRODUCTION

Barbara D. Wick is entering her 6th year of remission from breast cancer. She
underwent extensive chemotherapy as treatment for her cancer and assumed after
treatment termination she would soon return to her pre-cancer life. Her new reality posttreatment, however, is starkly different.
“I need to write everything down immediately,” Wick described during an
interview with the New York Times in 2013 “including appointments, doctors’
comments, ideas of things to do, and using more than one modality – listening and
writing – reinforces my ability to remember the information.”. Even six years following
the termination of her treatment, Wick continues to report cognitive impairments,
particularly with focus and retaining information that were not present previous to her
undergoing chemotherapy treatment.
Wick is not alone in a growing number of cancer survivors. Over the last few
decades, cancer treatment and survivability post-treatment have improved drastically.
Between early detection and improved treatment methods, survivability rates have
improved by about 20% between 1975 and 2006. The American Cancer Society and
National Cancer Institute estimate there to be 13.7 million cancer survivors in the US
alone, with a projected 18 million by 2022 (Siegel, 2016). In other words, the number of
patients surviving post cancer treatment is substantial and continuing to grow.
One common approach to the treatment of cancer is the use of chemotherapy.
Chemotherapy, by definition, works by stopping the growth and development of cells in
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the body. While this can be successful in limiting cancer, it is not exclusive to cancer
cells and can negatively impact healthy cells as well. Because of this, chemotherapy
brings with it its own host of side effects that can drastically impact a patient’s quality of
life post treatment. Among the reported side effects is cognitive impairment, known as
“Chemo Brain” or “Chemo Fog”.

Chemo Brain: Patient Reports and Cognitive Performance
Cognitive impairment following chemotherapy treatment, often called Chemo
Brain or Fog, largely impacts working memory, processing speed, focus and attention.
Up to 75% of people indicate cognitive impairment while undergoing chemotherapy
(Janelsins et al., 2014). Research surrounding Chemo Brain originated with patients selfreporting cognitive impairments following chemotherapy treatment. Initially, these
complaints were largely dismissed as being a psychological phenomenon rather than
neurological in nature. In the 1980s, researchers began to explore the impact of
chemotherapy on cognition.
Researchers began investigating the impact of chemotherapy on cognition by
using standardized tests. Silberfar et al. (1980) had subjects who were undergoing
chemotherapy perform neuropsychological testing before and after treatment to evaluate
its potential impact. They found chemotherapy patients had significantly lower cognitive
scores compared to controls. With this finding, researchers continued to evaluate the
effects of chemotherapy on cognition using a variety of assessment methods.
Early studies focused on evaluating patient’s cognitive abilities shortly following
chemotherapy treatment, mostly 6 months post treatment or less. This approach has a
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variety of issues. Firstly, during the first few months following chemotherapy treatment,
increased stress and fatigue levels may negatively impact performance on standardized
tests compared to normative controls (Ferguson & Ahles, 2003). For example, 95% of
Komaki and colleagues (1995) subjects had impairments on standardized
neuropsychological assessment shortly following treatment termination. Similarly,
Wieneke and Dienst (1995) found 75% of their subjects performed two standard
deviations below published norms 6 months post treatment. In a third test, Janelsins et al.
(2014) report up to 35% of patients having cognitive impairment in both patient reports
and standardized testing years post treatment. With these results and observations,
researchers began to investigate further the potential long-term impact of chemotherapy
treatment on cognition.
One of the first long-term studies was conducted in 1999 by Schagen and
colleagues who assessed chemotherapy patients two years post treatment. Those
receiving chemotherapy treatment performed significantly worse on neuropsychological
tests (used to evaluate cognitive abilities) than controls. Similarly, Wefel et al. (2010)
found cognitive decline in the domains of learning and memory, executive function, and
processing speed one year post-treatment. Other studies have noted decreased
performance in information processing and deficiencies in the executive control network
one-year post treatment (Chen et al., 2014). Recently, a study conducted by StoutenKeperman et al. (2015) compared cognitive brain function in breast cancer survivors of
similar illness severity who underwent chemotherapy treatment before treatment, two
years following treatment and 11.5 years following treatment. The patients were
separated into three groups; one group was comprised of individuals receiving high dose
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chemotherapy, one group received conventional dosing chemotherapy, and one group did
not receive any chemotherapy treatment. Researchers had each group undergo
neuropsychological testing prior to chemotherapy treatment, two years post treatment,
and 11.5 years post treatment. These long-term effects can have a profound negative
effect on the quality of life of survivors. Today, it is largely accepted that the symptoms
of Chemo Brain can be long lasting (greater than 10 years) and can negatively impact life
post treatment for survivors.
Although research concerning Chemo Brain has increased significantly since the
1980’s, limited progress has been made to understand the mechanisms behind cognitive
impairment in Chemotherapy patients. Many roadblocks have slowed progress; lack of
longitudinal studies, major differences in experimental designs (making it hard to
compare results) and a lack of control in patient treatment techniques are just a few of the
challenges that researchers face (Vardy et al., 2007). Although progress has been made,
many questions still stand.

Chemotherapy
Chemotherapy, at a basic level, works to prevent cellular proliferation (the
process by which there is an increase in the number of cells as a result of cellular growth
and division). Chemotherapy is separated into a variety of drug classes, depending on the
mechanism behind how they prevent cellular proliferation. These agents include
Alkylating Agents, Antimetabolites and Topoisomerase Interactive Agents, among
others. Because these agents work by distinct methods their impact on the body varies
between classes. It is important to note that although chemotherapy agents are classified
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into drug classes, the individual agents within a class may impact the body in unique
ways.

Alkylating Agents:
Alkylating Agents interact with one or both DNA strands to interfere with cellular
division (Han et al, 2008). In particular, the agent forms covalent bonds with a singular
DNA strand or causes a crosslink between the two strands (Seigers et al., 2011). This
suppresses DNA transcription and inhibits cellular division. One unique aspect to
Alkylating Agents is they trigger apotosis (or programmed cell death) and cellular
damage independent of the cell cycle. Cyclophosphamide is a commonly prescribed
Alkylating Agent that works by inducing apoptosis by forming DNA cross-links.
Antimetabolites:
Antimetabolites work by replacing necessary metabolites with nonfunctional
substitutes, resulting in the disruption of cellular growth and development. This class of
chemotherapy drugs is cell cycle dependent and is only active during the “S-phase” of the
cell cycle. Among antimetabolites, 5-Fluorouracil (5-FU) is the commonly studied. 5-FU
works by replacing pyrimidine, a key structure of DNA. It also blocks thymidylate
synthase, an enzyme used in the assembly of thymidine, a crucial molecule of DNA
synthesis (Seiger et al. 2011).

Topoisomerase Interactive Agents:
Topoiomerase is a crucial enzyme in the regulation of DNA replication. It works
by cutting the coiled DNA strands during replication to allow for the DNA to be copied
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(Seigers et al. 2011). These agents work by inhibiting or changing the action of
Topoisomerase, thereby limiting or stopping replication. One common example of this
agents is Doxorubicin.
Blood-Brain Barrier:
The blood brain barrier is a system within the central nervous system that only
allows certain substances to ross into the CNS. Polar molecules and gases can fairly
easily cross this barrier. The ability of chemotherapy agents to cross the barrier is agent
specific. Doxorubicin, 5-FU and Cyclophosphamide has been seen to potentially have the
ability to cross the barrier (Christie et al., 2012, Seigers et al., 2011). By having the
ability to physically access the brain, the chemotherapy agents may be able to have a
more profound impact.
Combination Therapy:
Often, a combination of various chemotherapy agents is used to treat cancer. This
treatment could include multiple chemotherapy agents from the same or different classes.
Because this is a common approach to treatment, many researchers argue further models
should include a combination of drugs rather than a singular drug in isolation. For
example, cyclophosphamide (an alkylating agent) and 5-fluorouracil (an antimetabolite)
are often used in conjunction with methotrexate (an antimetabolite). When evaluating the
role of chemotherapy on cognitive processing, it is important to remember common
clinical practice in treatment. The first step for researchers, however, is to understand
their individual roles.
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An important step in understanding the cognitive impairments expressed in the
patient population is understanding the effects of chemotherapy on the brain. The extent
of chemotherapy’s role and the underlying mechanisms behind Chemo Brain are an area
of debate (Fremouw et al., 2011). Chemotherapy treatment has been associated with
reduced neurogenesis and cell proliferation in the hippocampus, reduced or damaged
white matter, reduced survivability of neurons, neuroinflammation and the development
of Reactive Oxygen Species. These effects are destructive and could help explain
cognitive impairments seen with Chemo Brain.
Decreased Neurogenesis and Cell Proliferation
Within the hippocampus is a region known as the dentate gyrus. This area is a site
of neurogenesis and the integration of the new neurons into the brain. The process starts
with a Pluripotent Neural Stem Cell (NSC), which has the ability to develop into Neuron
Restricted Progenitor (NRP) Cells. This developmental period is known as cellular
proliferation. Cells then go into a weeklong period of differentiation, beginning to form
key neuronal structures known as dendrites and axons. After 2-3 weeks, neurons enter the
“survival phase” of development and the new neurons begin to receive excitatory input
from other axons. By 4-8 weeks, neurons are more fully integrated into the hippocampal
circuit and begin to look and act like fully mature neurons (Aimone et al., 2014).
The integration of maturing neurons is key to regulating normative cognitive
functioning. After development starts in the dentate gyrus, new neurons travel to the
granule cell layer. Interrupted migration and integration has been identified in
pathological cognitive conditions including neurodegenerative disease (Aimone et al.,
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2014). During proliferation and in the developmental steps following proliferation, cells
appear to be very vulnerable to chemotherapy agents (Dietrich et al., 2006).
The process of neurogenesis is crucial to positive cellular maturation and growth.
Studies have indicated that across classes, chemotherapy agents negatively impacts
neurogenesis in rodents; Alkylating Agents (Yang et al., 2012; Christie et al., 2012),
Antimetabolites (Seiger et., 2008, Yang et al., 2012, Dietrich et al., 2006),
Topoisomerase Interactive Agents ( Christie et al., 2012, Yang et al., 2012) and a
combination of Cyclophosphamide, Methotrexate, and 5-Fluorouracil (Briones et al.,
2011).
Researchers are able to measure neurogenesis by marking specific proteins during
the cell cycle, the process of cellular division that allows for the duplication of cells. Ki67 is a protein that is present during the active phases of the cell cycle, including the G1,
G2 S phase and mitosis, but is absent from resting cells. Because of this, Ki-67 is used as
an indicator protein of cellular replication and allows researchers to observe neurogenesis
levels in the hippocampus.
The mammalian brain contains two sites of continuous new neuron incorporation;
the olfactory bulb and the dentate gyrus (DG) region of the hippocampus (Aimone et al.
2007). The olfactory bulb houses migrated immature neurons that originate in the
subventricular zone. These neurons go on to integrate locally and serve as interneurons
(Aimone et al. 2007). The dentate gyrus is the site of origination and integration of new
neurons and plays a role in memory formation (Aimone et al. 2007). The subgranular
zone of the dentate gyrus houses a subset of neuronal progenitor cells that develop into
granule cells, the principle neuronal projections of the dentate gyrus (Aasebo et al. 2011).
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These cells go through a variety of developmental stages before finally integrating into
existing hippocampal circuitry (Aimone et al. 2007; Aasebo et al. 2011). It seems that the
distinct properties of new neurons are critical to memory formation. Among these are the
properties of plasticity and hyperactivity.
Plasticity is in reference to the nature of development of new neurons. It is
evident within the first week of development, new neurons do not display dendritic spine
arborization and thus are unlikely to have an effect on information processing (Aimone et
al. 2007; Aasebo et al. 2011). The next period (14-21 days), known as the “survival
phase”, is the time point at which granule cells have dendritic spine arborization and
mossy axonal projections that have the ability to synapse with information retrieval
portions of the hippocampus (Aimone et al. 2007; Aasebo et al. 2011). This period is
crucial to neurogenesis and is often referred to as the “critical period”.
Hyperactivity refers to a new neuron’s ability to induce long-term potentiation
faster and with less input than mature neurons (Aimone et al. 2007; Aasebo et al. 2011).
This is largely driven by the role of GABA receptors in new neurons. In fully developed
neurons, GABA receptors are inhibitory. In new neurons in the critical period, however,
GABA receptors act in an excitatory role largely due to the high concentration of chloride
ions present (Aimone et al. 2007). In fact, granule cells during this time point do not
have GABA receptors that are inhibitory and because of this will generate an action
potential well before a mature neuron.
It seems the integration of these new neurons could potentially play a role in
memory. While mature neurons are seemingly good at representing past encoded
information, new neurons are seemingly better at encoding novel events (Aimone et al.,
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2014; Aimone et al., 2011). In other words, new neurons are good at combining the
“what and where” of new experiences and then encoding them into memory. The
combination of immature and mature neurons is crucial for proper memory encoding
(Aimone et al., 2011). This ability is important for day-to-day cognitive functioning, and
a decrease in neurogenesis following chemotherapy treatment could negatively impact
memory abilities, potentially contributing to Chemo Brain.
Various chemotherapy agents decrease cellular proliferation in the dentate gyrus.
The majority of these studies observe declines in proliferation levels shortly following
chemotherapy administration. For example, Mustafa et al. (2008) and Yang et al. (2012)
noted decreases in hippocampal neurogenesis levels 12 days following 5-FU
administration. In another study, decreased hippocampal cellular proliferation was noted
7 days post administration of Methotrexate (an antimetabolite chemotherapy agent)
(Seigers et al., 2009). Christie et al. (2012) as well as Janelsins et al. (2010) noted
decreases in hippocampal neurogenesis levels one week following administration of
Cyclophosamide or Doxorubicin.
Few studies have looked at longer time points. Those studies include Dietrich et
al. (2006) who noted significantly decreased cell proliferation in adult mice one day post
administration of BCNU or Cisplatin (both alkylating agents) but also saw a continued
decrease 42 days following the administration of chemotherapy. Even after 42 days, cell
proliferation levels in chemotherapy-administered mice did not reach controls levels.
Another study was conducted by Han et al. (2008) evaluated the effect of 5-fluorouracil
on cellular proliferation. Proliferating cells immediately following treatment were
decreased in the subventricular zone and were continually decreased below control levels
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at the 56 day and 6 month time point post administration. These results indicate the
potentially extensive long-term effects chemotherapy can have and highlight the need for
further study. 	
  
Reduced or Damaged White Matter
White matter, also known as glial cells, are considered the support cells that help
neurons in the brain. Glial cells start as a pluripotent neural stem cell and develop into a
progenitor cell known as glial restricted pre-cursor cells. These cells go on to become
astrocytes or oligrodendrodrocyte-type-2 astrocytes. If the cells become
oligrodendrocyte-type-2 astrocytes, they then go on to become oligodendrocytes, the key
component of myelin in brain cells. Myelination is a crucial aspect to cognitive
functioning, helping increase processing speed down an axon.
Studies have indicated chemotherapy can reduce the survivability of
oligodendrocytes (Dietrich et al., 2006). Researchers evaluated the effects of various
levels of Cytarabine (an antimetabolite chemotherapy agent) on oligodendrocytes as well
as cancer cells. Even at small doses, oligoendrocyte survivability dropped from 100% to
about 60%. This profound impact was more damaging to oligodendrocytes than to cancer
cells. These effects were also detrimental to oligodendroycte progenitor cells. In other
words, chemotherapy could not only be impacting the oligodendrocyte themselves, but
also limiting the generation of new oligodendrocytes.
Other studies have noted a long-term impact of chemotherapy on
oligrodendroctye precursor cells. Researchers evaluated BrdU labeled cells as a way to
evaluate the division of the progenitor cells in the hippocampus. One day following
treatment of 5-fluorouracil (an antimetabolite chemotherapy agent) had reduced division
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of oligodendrocyte progenitor cells compared to controls. Fifty six days post treatment,
this reduction was still present. (Han et al., 2008).
Other studies have found myelin to be significantly reduced following
chemotherapy treatment (Seigers et al., 2011). In addition, damage to myelin integrity has
been noted. For example, researchers have noted a reduction in myelin thickness as well
as damaged and degraded myelin sheaths following chemotherapy treatment (Han et al.,
2008; Briones et al., 2014; Deprez et al., 2011). Similarly, other studies have noted a
decrease in myelin basic protein following chemotherapy treatment (Han et al., 2008;
Briones et al., 2014).
Neuronal Survivability
Others have evaluated the survivability of neurons following chemotherapy
treatment. Terminal deoxynucleotidylransferase-mediated dUTP nick end labeling, or
TUNEL+, labeling is used to measure cells undergoing apoptosis, or cell death.
Systematic chemotherapy with cytarabine has lead to prolonged cell death, even 56 days
post treatment (Dietrich et al., 2006; Han et al., 2008).
In addition, other studies have used TUNEL+ to evaluate cell death at even longer
time points. Even at six months post chemotherapy treatment, the percent of TUNEL+
cells in the central nervous system was still higher than controls (Han et al., 2008).
Reactive Oxidative Species
One final mechanism by which chemotherapy impacts the brain is by the
production of Reactive Oxygen Species, or ROS. ROS is naturally in the body as a
byproduct of breathing, but at elevated levels it can be damaging to the body. The body
counteracts ROS with antioxidants; however, chemotherapy targets antioxidants and
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decreases their production (Angsutaraux, P et al., 2015). High ROS levels, in addition to
the reduction of their destroyers (antioxidants), can cause extensive cell damage.

Preventative Treatments
Antidepressants:
One approach researchers have begun to investigate is the use of preventative
treatments to potentially help limit the impact of chemotherapy on the brain. One of these
treatment options is antidepressants, in particular Fluoxetine. Fluoxetine falls under the
category of selective serotonin reuptake inhibitors (SSRI’s). Serotonin is associated with
cognitive function and may play a role in cognitive ability (Seigers et al., 2011). In
addition to increasing serotonin levels, SSRI’s are associated with increased levels of
neurogenesis and proliferation (Surget el al., 2012). Studies have indicated mice treated
with fluoxetine for 21 days had increased levels of hippocampal proliferation (Wang et
al., 2008). By increasing proliferation levels prior to treatment, it is hypothesized that the
treatment could potentially help protect against or reverse reductions seen as a result of
chemotherapy. Treatment with antidepressants has been seen to reverse these decreases in
proliferating in other studies (Dranovsky & Hen, 2006), indicating it could potentially
work similarly to combat the effects seen in Chemo Brain.
In addition to promoting neurogenesis and cellular proliferation, antidepressant
may also work as a neuroprotectant to combat cognitive impairment seen in patients
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undergoing chemotherapy treatment. One study found that rats undergoing 5-fluorouracil
treatment had reduced neurogenesis in the hippocampus, while animals that received 5fluorouracil while also taking fluoxetine displayed no significant decreases in
neurogenesis compared to controls (ElBeltagy et al., 2010). It is important to note that the
fluoxetine administration was given at the same time 5-fluorouracil was given. Similarly,
another study found success with using fluoxetine as a pre-treatment for rats undergoing
treatment with the chemotherapy agent methotrexate. Animals just receiving
methotrexate showed decreased cellular proliferation within the dentate gyrus of the
hippocampus as well as decreased cell survivability. Animals who received methotrexate
in addition to fluoxetine showed no decrease in survivability or proliferation following
treatment (Lyons et al., 2011). By giving chemotherapy patients an agent that increases
neurogenesis and cellular proliferation, such as an SSRI, it potentially could help prevent
the noted decreases in neurogenesis following chemotherapy treatment.

Gaps in Literature
It is evident that at short-term time points, many chemotherapy agents can
negatively impact levels of neurogenesis. Few studies have investigated the long-term
impact of chemotherapy on neurogenesis. Although there have been noted decreases in
neurogenesis levels at 42 days following BCNU or Cisplatin administration (Dietrich et
al., 2006), many common chemotherapy agents such as Cyclophosamide or Doxorubicin
have yet to be studied at similar time points.
5-FU has been seen to impact neurogenesis levels at the longer time points of 56
day and 6 months following administration (Han et al., 2008). The administration of
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fluoxetine with various chemotherapy agents, including 5-FU, has been noted to prevent
decreases in neurogenesis compared to animals receiving the chemotherapy alone when
neurogenesis levels have been measured shortly after chemotherapy administration
(Lyons et al., 2011; ElBeltagy et al., 2010). Researchers have yet to investigate how
neurogenesis levels are impacted by the use of fluoxetine as a pre-treatment to the
administration of chemotherapy such as 5-FU at long time points post chemotherapy
administration.

METHODS
Experiment 1
Aim of Experiment 1
Studies have shown that chemotherapy agents can reduce neurogenesis and
cellular proliferation within the hippocampus a few weeks post treatment (Dietrich et al.,
2006; Han et al., 2008; Mustafa et al., 2008; Seigers et al., 2008; 2009; Janelsins et al.,
2010; Christie et al., 2012; Yang et al., 2012). Few studies have investigated the effects
of chemotherapy at long-term time points as well as the effects of different classes of
chemotherapy agents on neurogenesis.
At 1 week post administration, studies have found the chemotherapy agents
cyclophosphamide and doxorubicin can reduce neurogenesis following treatment
(Janelsins et al., 2010; Christie et al., 2012). The long-term effects of these compounds
on neurogenesis is largely unknown. In addition, the potential differences in timing
effects of the two compounds is also unknown. This study looks to evaluate neurogenesis
56 days and 6 months post cyclophosphamide and doxorubicin administration.

	
  

	
  

15	
  

Cyclophosphamide (an alkylating agent) and doxorubicin’s (a topoisomerase
interactive agent) long-term impact on hippocampal neurogenesis will be evaluated.
Using the proliferation marker Ki-67, the study will be able to assess neurogenesis.
Neurogenesis is not specific to just proliferating neurons, but also white matter. In the
region we are assessing, however, nearly 90% of the proliferating cells are neurons. Early
and late effects of the chemotherapy treatment at 56 day and 6 months post
administration will be evaluated. At both 56 day and 6 months, I hypothesize that animals
treated with cyclophosphamide or doxorubicin will have decreased amounts of
proliferating cells within the dentate gyrus of the hippocampus compared to controls.
Methods and Materials Experiment 1
Subjects: 37 C57BL/6J male mice aged 8-9 weeks were obtained from Jackson Labs in
Bar Harbor, Maine. The animals were acclimated to our animal colony for approximately
two weeks prior to treatment. Mice were socially housed with 3-4 mice per cage in a 70ºF
room using a twelve-hour light dark cycle (7:00 – 19:00) with food and water as needed.
Animals were randomly assigned to one of three treatment conditions: doxorubicin,
cyclophosphamide or saline controls.
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Fig. 1. Outlines methodology for experiment, including chemotherapy administration and
tissue collection at specific time points.
Chemotherapy Treatment: Each mouse group received intrapertitoneal injections over a
period of 7 days (Figure 1). Cyclophosphamide (120mg/kg diluted in 0.9% saline; Acros
Organics), doxorubicin (5mg/kg diluted in 0.9% saline; Fisher Scientific) or control
saline (0.9% NaCl) were used (Figure 1). These injections were administered following
the methods used in Janelsin et al. (2010) on days 1, 4, and 7, totaling 3 injections for
each animal. One major difference in our study, however, is the dosage amount. An
increased dosage was used in an attempt to maximize potential long-term negative effects
of the treatment on the brain. This amount was derived from tests with C57BL/6J mice
and equaled the maximum amount the mice could survive in conjunction with typical
patient dosages in humans. Because the effects to chemotherapy can vary as a function of
circadian rhythm (Focan, 1995), mice were treated at approximately the same time, 8-9
hours post light onset. Weight was monitored daily for approximately 4 weeks, then
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every other day until 56 days post treatment. For the 6 month group, mice were weighed
once a week rather than daily after day 56. Teeth length was also monitored, trimming
when necessary, as overgrowth can lead to weight loss.
Tissue Collection: Animals were sacrificed and transcardially perfused with 0.9% saline
followed by 4% paraformaldehyde (PFA) at 56 days (6 saline controls, 6
cyclophosphamide, and 3 doxorubicin) and 6 months (8 saline controls, 9
cyclophosphamide, and 5 doxorubicin) following their last chemotherapy injection.
Brains were then extracted and submerged in PFA, then a 30% sucrose solution, then
flash frozen. Six series of 40 µm coronal sections were cut. Each single series tissue for
an animal selection includes the entire hippocampus with approximately 10 section of
tissue for each animal. The slices were then transferred into a 0.05% potassium
phosphate buffered saline solution (KPBS), then moved into an antifreeze cyroprotectant
and stored at -20oF.
Immunohistochemical Staining: An aviden/biotin-based peroxidase Vectastain Elite
ABC Kit (Rabbit IgG) system (Vector Laboratories, Inc.) was used for
immunohistochemical staining on prepared tissue. We utilized Ki-67 rabbit primary
antibodies (Wak Pure Chemical Industries, Ltd.) with the Elite ABC kit for the detection
of Ki-67 proteins. By using a titration series, were we able to identify the ideal Ki-67
antibody concentration for our tissues samples, following the Hoffman et al. (2008)
recommended immunohistochemical staining method. After the tissue was selected, it
underwent six, 10 minutes rinses with 0.05% KPBS to wash the preserved tissue.
Afterward, it was placed in a 1% hydrogen peroxide, 0.05% KPBS solution for 15
minutes. Following this, the tissue was once again rinsed in 0.05% KPBS 4 times for 5
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minutes each, then incubated in a 1:4,000 Ki-67 rabbit primary antibody diluted in 0.05%
KPBS/0.4% Triton X-100 solution for 1 hour at room temperature. The tissue then was
stored in the refrigerator (approximately 33ºF) for 48 hours. Afterward, the tissue was
thoroughly rinsed in 0.05% KPBS 10 times for 6 minutes each and then incubated in a
(1:500) biotinylated, affinity-purified anti-immunoglobulin secondary antibody (Vector
Laboratories, Inc.) diluted in 0.05% KPBS/0.4% Triton X-100 solution at room
temperature for 1 hour. After 5, 10 minute rinses in 0.05% KPBS the tissue was
incubated in an avidin biotinylated enzyme complex (ABC) diluted in 0.05% KPBS/0.4%
Triton X-100 solution at room temperature for 1 hour. Following this incubation the
tissue underwent 3, 5 minute rinses each in 0.05% KPBS and then was rinsed again 3
times for 5 minutes each in 0.175% sodium acetate. The tissue then underwent the final
incubation in a nickel enhanced DAB chromogen solution (2.5% Ni + 2% DAB) for 25
minutes. After this final incubation the tissue was rinsed 3 times for 5 minutes each, in
0.175% sodium acetate, to stop the chemical reaction, followed by two final rinses in
0.05% KPBS for 10 minutes each. Stained tissue slices were then floated in .0125%
KPBS and then air-dried mounted on microscope slides for 24 hours. Dried slides were
dehydrated using graduated EtOH solutions (70-100%) and cleared with HistoClear
(National Diagnostics Inc.). Following drying, the slides were then cover slipped using
HistoMount (National Diagnostics Inc.) and dried again for 24 hours.
Tissue Analysis: The number of Ki-67 positive cells within 10 slices of the dentate gyrus
of the hippocampus of each animal was counted by eye. This procedure follows standard
unbiased stereological estimation protocol as defined by Noori & Fornal (2011).
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Experiment 2
Aim of Experiment
This study is looking to evaluate the effects of the chemotherapy agent 5-FU on
neurogenesis in the dentate gyrus of the hippocampus of mice. Han et al. (2008) found a
decrease in neurogenesis in the SVZ region at 1 week, 56 days and 6 months post
treatment, but only noted decreases in neurogenesis within the dentate gyrus at 14 days
and 6 month. This study looks to repeat these findings evaluating neurogenesis levels in
the dentate gyrus in mice at 56 day and 6 month following 5-FU treatment. In addition to
evaluating the effects of chemotherapy alone, this study will also evaluate the effects of
using fluoxetine as a pretreatment to 5-FU on neurogenesis levels. In the two time points
the study will be evaluating the role the compound plays in preventing or protecting from
deficits in neurogenesis following 5-FU treatment.
It is evident that Fluoxetine can boost neurogenesis (Ramirez-Rodriguze et al.,
2011; Duman et al., 2000,2001; Malberg et al., 2000; Dranovsky & Hen, 2006; Czéh et
al. 2007). Other studies have also found that fluoxetine can prevent or even restore
deficits in neurogenesis when administered with 5-FU (ElBeltagy et al., 2010) at 1-2
weeks post treatment termination.
Research has yet to investigate the long-term potential protective abilities of
neuroprotectants. Because of the given protective and restorative effects of fluoxetine, I
hypothesize that at 56 day and 6 month post treatment, 5-FU administered that also
receive a pretreatment of fluoxetine will have higher levels of cellular proliferation than
those animals treated with 5-FU alone.
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Methods and Materials Experiment 2:
Subjects: 41 C57BL/6J male 10-11 week old mice were used for the study. Mice arrived
from Jackson labs and were acclimated to our animal colony for approximately 2 weeks
before treatment began. Animals are housed socially (3-4 mice per cage) in a
temperature ( approximately 70oF) and light/dark controlled (7:00 – 19:00) environment
with food and water as needed. Animals were randomly assigned to one of three
treatment conditions: saline controls, 5-FU and Saline, or 5-FU and fluoxetine. Animals
were administered fluoxetine through drinking water. The mice were housed by group to
ensured they were receiving only their assigned treatment.

Fig. 2. Outlines methodology for experiment, including Fluoxetine pretreatment,
chemotherapy administration and tissue collection at specific time points.
Neuroprotectant Water Treatment: As evident in Figure 2, the neuroprotectant
fluoxetine was administered prior to the administration of 5-FU. The neuroprotectant was
administered via drinking water, following the protocol outlined in ElBeltagy et al
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(2010). There are a variety of benefits to administering fluoxetine via drinking water
versus injection treatment. Firstly, it allows for long-term treatment, which allows our
study to increase neurogenic levels prior to treatment with 5-FU. Secondly, it reduces
unnecessary stress resulting from repeated injections. Every 4 days, water was weighted
and changed as a way to measure water intake and ensure the target dose of fluoxetine
was reached. The target dose for was calculated using previous studies that indicated
peak neurogenic effects pretreatment from 10mg/kg to 15 mg/kg (Lyons et al., 2011;
Lesemann et al., 2012). Other studies have utilized this 21-day timeline for water
administration (ElBeltagy et al., 2012, Ramirez-Rodriguez et al., 2011; Dranovsky &
Hen, 2006) prior to chemotherapy treatment. Water intake was calculated by the
difference in averages of daily evaporation levels (3 control water bottles in empty cages
were used) and bottle weight divided by average water consumed by amount of days and
animal/cage. Figure 2 further illustrates the dosage timeline.
Chemotherapy and Neuroprotectant Treatment: Intraperitoneal (i.p.) injections were
administered to mice in each group over 5 days (see Figure 2). Following procedure
outlined in Han et al., (2008), 5-FU (70mg/kg diluted into 0.9% saline; Sigma-Aldrich)
or control saline (0.9% NaCl) injections were administered on days 1, 3, and 5. Our study
utilized maximally tolerated dosages for C57BL/6J mice calculated by previous dosage
studies done within our lab. Due to the effects of circadian rhythm on toxicity and
tolerance (Focan, 1995), our study treated mice at a similar approximate time (8-9 hours
after light onset).
Although our study originally gave neuroprotectant treatment via water prior to
chemotherapy treatment, during chemotherapy treatment we turned to injection
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treatments for administration. Animals treated with chemotherapy often decrease their
water intake as a result of their treatment. Because of this, our lab could not ensure the
mice were receiving consistent amounts of neuroprotectants and we turned to injection
treatment. Neuroprotection injections of fluoxetine (15mg/kg diluted into 0.9% saline;
Sigma-Aldrich), or control saline (0.9% NaCl) were delivered 20 minutes prior to
chemotherapy and once every 24 hours for a total of 5 injections per animal. Treatment
timelines for the neuroprotectant and 5-FU is outlined in Figure 2. For 4 weeks, weight
was measured daily. Afterward, mice were weighted every other day until day 56. Post
day 56, the mice were weighed weekly. Teeth were trimmed when necessary for
prevention of overgrowth which can result in weight loss.
Tissue Collection: The same tissue collection procedure used in Experiment 1 was used.
Immunohistochemical Staining: The same immunohistochemical staining procedure
used in Experiment 1 was used.
Tissue Analysis: The same tissue stain analysis protocol used in Experiment 1 was used.

RESULTS
Experiment 1
A two-way ANOVA revealed there was not a significant effect of treatment on
mean proliferating cell amount [F(2, 27) = .067, p = .936]. A two-way ANOVA indicated
there was a significant effect of day on mean proliferating cell amount [F(1,27) = 13.861, p
= .001] and there was no significant effect of the interaction of condition and day on
mean proliferating cell amount [F(2, 27) = 1.232 p = .308].
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Fig. 3: Figure 3 shows the mean number of proliferating cells for 10 slices of the dentate
gyrus of the hippocampus per animal as a function of treatment and days following
chemotherapy administration. Error bars represent + 1 standard error of the mean.
Experiment 2
A two-way ANOVA found no significant effect of treatment on mean
proliferating cell amounts [F(2, 33) = .423, p = .659]. There was a significant effect of day
on mean proliferating cell amounts [F(1, 33) = 88.334, p = .000] and no significant effect
of treatment by day interaction [F(2, 33) = 2.238, p = .123].
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Mean Number of Proliferating Cells

Experiment 2
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Fig. 4. Figure 4 shows the mean number of proliferating cells for 10 slices of the dentate
gyrus of the hippocampus per animal as a function of treatment and days following
chemotherapy administration. Error bars represent + 1 standard error of the mean.

DISCUSSION
In the present study, two experiments explored the long-term impact of
chemotherapy on neurogenesis as well as the potential use of a preventative treatment
method. In the first experiment, a mouse model was used to investigate the impact of
Cyclophosphamide and Doxorubicin on neurogenesis at 56 day and 6 months following
administration termination. In the second experiment, the study looked to explore the
impact of the protective treatment of Fluoxetine given prior to the administration of 5-FU
on cellular proliferation in mice at 56 day and 6 months following treatment termination.
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In experiment 1, I hypothesized observing a difference in mean number of
proliferating cells as a function of Cyclophosphamide or Doxorubicin treatment,
potentially seeing differences between the treatment methods. Although there was not a
significant effect of Cyclophosphamide or Doxorubicin treatment on the amount of
proliferating cells, there was a significant effect of day (56 days versus 6 months). These
results are consistent with other studies which show a decrease in neurogenesis as part of
the aging process. Studies have found that the ageing rodent brain has an exponential
decrease in dividing cells between the age of 1 and 9 months (Seib&Martin-Villalba,
2015). The present study’s results also indicate a decrease in neurogenesis over time,
indicating our immunohistochemistry methods were largely successful and are not the
source of why the study did not find an effect of chemotherapy on neurogenesis.
In experiment 2, I hypothesized seeing an increase in cellular proliferation levels
in mice treated with protective treatment in addition to 5-FU compared to mice treated
with 5-FU alone. Results indicated there was not a significant effect of the addition of
protective treatment with the administration of 5-FU as compared to controls. Like
experiment 1, there was a significant effect of day on neurogenesis levels (56 day versus
6 months). Although the results did not find a significant effect of treatment on the 5-FU
animals, this alone cannot definitely say that 5-FU doesn't have an impact on
neurogenesis at 56 day and 6 month times points. Other studies have noted decreases in
neurogenesis following 5-FU treatment at similar time points, indicating the compound’s
potential to negatively impact the process (Han et al. 2008).
Our results measured how cellular proliferation was effected as a result of
chemotherapy treatment. Although Ki-67 marking is used as a hypothetical measure of
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neurogenesis, it only has the ability to identify actively dividing cells. Because of this, the
use of an additional stain is necessary to adequately measure neurogenesis. One of the
most commonly used stains is Doublecortin, which is nearly exclusively expressed in
developing neurons and continually expressed for 2-3 weeks as the cells mature. The
present study was unable to conduct double staining for this project due to time
constraints but considers it an important aspect of future study on chemotherapy and its
effects on neurogenesis.
Although these findings indicate there is a decrease in cellular proliferation as a
result of time, they do not speak to the survivability of the newly generated cells. A key
piece of survivability of neural cells is their integration into neuronal circuits.
Interruption of integration of these cells has been linked to disruptions in cognitive
function (Aimone et al. 2014). It is possible that Cyclophosphamide and/or Doxorubicin
could be more detrimental to the survivability of these cells rather than their generation.
Other studies have noted a decrease in the survivability of developing neurons after
undergoing chemotherapy treatment (Han et al., 2008; Dietrich et al., 2006). One way to
potentially utilize a stain that measures the survivability of the newly generated cells.
It may also be beneficial in future study to better model the patient population.
Studies could investigate the impact of having cancer while receiving chemotherapy
treatment on neurogenesis levels. Furthermore, it may be beneficial to investigate the
impact on female and elderly mice in future studies as well to better represent the patient
population.
The study chose C57BL/6J mice due to their increased neurogenesis levels as
compared to other strains (Kim et al., 2009). This allowed our study to more easily
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identify changes in neurogenesis levels as a result of treatment. In comparison, other
long-term studies such as Dietrich et al. (2006) and Han et al. (2008) used CBA strain
mice. Although we did not observe any significant differences in cellular proliferation
following treatment, it is possible that C57BL/6J mice are inherently better at protecting
or repairing damages from processes that reduce proliferation. This strain could
potentially not be effected by chemotherapy treatment in a way that other strains of mice
with more normative levels of neurogenesis may be. This process of thinking can also be
applied to the human population. It is possible that certain individuals are born with an
ability to withstand damages to neurogenesis levels while others aren’t. This could
explain why only a subset of individuals experience symptoms of Chemo Brain. Further
study of genetic differences among individuals and how this impacts neurogenesis is
crucial to future study.
It is not likely that our methods of chemotherapy administration were the cause of
our results. Dosages given to our mice were impacting the mice in such a way that it was
evident the treatment was effective. In data that is not listed, mice in Cyclophosphamide,
Doxorubicin and 5-FU groups from the present study all lost weight, a classic side effect
of chemotherapy treatment. Mice that underwent cyclophosphamide administration in
particular exhibited common side effects of greying hair and overgrowing of teeth. In
addition to presenting side effects indicating the chemotherapy treatment was impactful,
the study’s dosages were consistent with other similar studies (Janelsin et al. 2010).
The present study results are consistent with those recently published by Seigers
et al. (2016). In their study, they found no significant effect of treatment of
Cyclophosphamide, Doxorubicin or 5-FU on neurogenesis in the dentate gyrus of
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C57BL/6J mice 3 weeks after treatment. These results are a shorter time frame, but are
similar to our study’s results indicating that chemotherapy agents may not significantly
impact proliferation. The role of chemotherapy on neurogenesis and cellular proliferation
may be less impactful than hypothesized.
It is possible that new neurons generated through neurogenesis do not play as big
a role in the types of impairment that Chemo Fog patients display as originally thought.
Although it is hypothesized that the combination of new and mature neurons are critical
to working memory, it is entirely possible that memory processes are not majorly affected
by losses in new neurons. Similarly, the integration of new neurons is often regarded as
crucial to memory processes. It is possible that chemotherapy treatments do not affect the
integration process, or effect neurogenesis at high enough levels to make a significant
impact on memory.
Although many studies have researched the impact of chemotherapy agents on
brain histology, few have investigated the time points that reflect the long-term or
potentially permanent impairment the treatment can have. Although our results did not
indicate significant effects of chemotherapy treatment on cell survivability, this is not to
say that the chemotherapy agents in question do not affect cellular proliferation,
neurogenesis, or survivability in all individuals or species. Looking ahead, it is necessary
to utilize a double stain to better understand chemotherapy’s specific impact on
neurogenesis as well as its impact on survivability of neural cells. For example, one
major difference in the present study and in Han et al. (2006) is the stains utilized to
measure neurogenesis. Han et al. (2006) utilized a double stain of a stain known as
Doublecortin and BrdU while we only used a Ki-67 stain. Further research is necessary to
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understand how chemotherapy impacts the brain and how the symptoms of Chemo Brain
can be prevented or treated.
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